<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32484726</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5-6</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study.</ArticleTitle><Pagination><StartPage>373</StartPage><EndPage>379</EndPage><MedlinePgn>373-379</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1771732</ELocationID><Abstract><AbstractText><i>Background</i>: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dysexecutive or behavioral dysfunction, is detected in 30-50% of patients affected by amyotrophic lateral sclerosis (ALS) at diagnosis. Such condition considerably influences the prognosis, and possibly impacts on the decision-making process with regards to end-of-life choices. The aim of our study is to examine the changes of cognitive and behavioral impairment in a large population of ALS from the time of diagnosis to a 6-month follow-up (IQR 5.5-9.0 months), and to examine to what extent the progression of cognitive impairment affects survival time and rate of disease progression.<i>Methods</i>: We recruited 146 ALS patients classified according to revised criteria of ALS and FTD spectrum disorder. In a multidisciplinary setting, during two subsequent visits we examined clinical features with ALSFRS-r score, FVC% and BMI, and cognitive status with an extensive neuropsychological evaluation.<i>Results</i>: At second examination, one-third of patients showed a worsening of cognitive impairment, namely 88% of ALSbi, 27% of ALSci, 40% of ALScbi, and, interestingly, also 24% of cognitive normal ALS developed a significant cognitive dysfunction. We find that those who changed their cognitive status presented a lower ALSFRS-r score at t1 and a shorter survival time compared to those who did not change, regardless of the type of cognitive impairment.<i>Conclusion</i>: We show how cognitive disorders in ALS patients can not only be present at diagnosis, but also manifest during disease and influence the progression of motor deficit and the prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bersano</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3rd Neurology Unit and Motor Neuron Diseases Centre, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnelli</LastName><ForeName>Maria Francesca</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solara</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iazzolino</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peotta</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Facchin</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0604-5029</Identifier><AffiliationInfo><Affiliation>Department of Psychology, University of Milano Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1st Neurology Unit, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1st Neurology Unit, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1st Neurology Unit, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1st Neurology Unit, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis</Keyword><Keyword MajorTopicYN="N">cognitive impairment</Keyword><Keyword MajorTopicYN="N">fronto-temporal dementia</Keyword><Keyword MajorTopicYN="N">longitudinal study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32484726</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1771732</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>